Losmapimod - Fulcrum Therapeutics
Alternative Names: 856553; FTX-1821; GS856553; GSK 856553; GW 856553; GW856553XLatest Information Update: 20 May 2024
At a glance
- Originator GlaxoSmithKline
- Developer Fulcrum Therapeutics; GlaxoSmithKline; GSK
- Class Amides; Analgesics; Anti-inflammatories; Antidepressants; Antihyperlipidaemics; Antirheumatics; Antivirals; Cardiovascular therapies; Cyclopropanes; Fluorobenzenes; Pyridines; Small molecules; Vascular disorder therapies
- Mechanism of Action DUX4 protein inhibitors; P38 mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Acute coronary syndromes; COVID 2019 infections; Facioscapulohumeral muscular dystrophy
- Phase II Chronic obstructive pulmonary disease; Focal segmental glomerulosclerosis
- No development reported Inflammation
- Discontinued Atherosclerosis; Dyslipidaemias; Major depressive disorder; Neuropathic pain; Rheumatoid arthritis
Most Recent Events
- 14 May 2024 Fulcrum Therapeutics announces intention to submit NDA to US FDA for Facioscapulohumeral muscular dystrophy in the US
- 13 May 2024 Losmapimod licensed to Sanofi ex USA territories for the treatment of Facioscapulohumeral muscular dystrophy
- 13 May 2024 Fulcrum Therapeutics announces intention to submit regulatory application in Japan for Facioscapulohumeral muscular dystrophy